glp-1 news today 2025 Agonists Weight Loss Drugs Market Report, 2025-2030 GLP-1 Pipeline Update: August 2025

Description

This article breaks down the costs associated with GLP-1 drugs and what to consider

Cardiovascular outcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed the cardiovascular benefits of glucagon-like peptide 1 receptor agonists (GLP-1RAs), including reduced cardiovascular mortality, lower ...

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

These one-page guides will answer your patient's most common questions when starting a GLP-1 RA or SGLT2i medication..

Glucagon-like peptide-1 receptor agonist (GLP-1RAs) and more recently Twin-Cretins (GLP+GIP) are frequently used for patients with diabetes and associated obesity